Huadong Medicine Co., Ltd (000963.SZ)
- Previous Close
39.01 - Open
38.97 - Bid 39.23 x --
- Ask 39.25 x --
- Day's Range
38.51 - 39.35 - 52 Week Range
25.96 - 40.80 - Volume
10,873,000 - Avg. Volume
13,487,960 - Market Cap (intraday)
68.83B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
19.33 - EPS (TTM)
2.03 - Earnings Date Apr 25, 2025
- Forward Dividend & Yield 0.93 (2.38%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
46.25
Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. It operates through Pharmaceutical Industry, Pharmaceutical Business, Aesthetic Medicine, and Industrial Microbiology segments. The company distributes Chinese and western medicines, Chinese herbal medicines, and medical instruments; and immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, antibiotic drugs, medical beauty field products, and medical apparatus and equipment. It also manufactures and sells antibiotics, Chinese patent medicines, synthetic drugs, and genetic engineering drugs; and engages in pharmaceutical logistics and industrial microbiology activities. In addition, the company provides business, leasing, and warehousing services. The company has a strategic cooperation agreement with SynerK PharmaTech (Suzhou) Co., Ltd. to develop the small nucleic acid (siRNA) drug SNK-2726, an angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine Co., Ltd was incorporated in 1993 and is headquartered in Hangzhou, China.
www.eastchinapharm.com18,265
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000963.SZ
View MorePerformance Overview: 000963.SZ
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000963.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000963.SZ
View MoreValuation Measures
Market Cap
68.43B
Enterprise Value
67.38B
Trailing P/E
19.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
2.84
Enterprise Value/Revenue
1.60
Enterprise Value/EBITDA
15.18
Financial Highlights
Profitability and Income Statement
Profit Margin
8.44%
Return on Assets (ttm)
7.37%
Return on Equity (ttm)
15.08%
Revenue (ttm)
42.23B
Net Income Avi to Common (ttm)
3.56B
Diluted EPS (ttm)
2.03
Balance Sheet and Cash Flow
Total Cash (mrq)
3.71B
Total Debt/Equity (mrq)
10.86%
Levered Free Cash Flow (ttm)
517.83M